Osimertinib medication has recently appeared as a promising therapy possibility, particularly for patients with NSCLC (NSCLC), especially those with EGFR mutation-positive tumors.Treating NSCLC is associated with the important issue of potential bone metastasis development, which can significantly impact patients' quality of living and survival chances.The article aims to provide a complete overview of administering Osimertinib medication bone metastasis, involving the investigation of basic mechanisms, therapy strategies, and accompanying challenges.A third-line EGFR tyrosine kinase inhibitor (TKI), Osimertinib medication, has shown remarkable efficacy in treating NSCLC patients with EGFR alterations.bone metastasis remain…
